Sulforaphane is the compound that gives broccoli sprouts their reputation, and it is a difficult guest in a gummy. Brands see demand for a sprout-derived supplement in a convenient format, but the ingredient fights the manufacturing process at nearly every step: heat, water, oxygen, and pH. Making a stable version takes engineering work at every step.
Why Sulforaphane Is Hard to Put in a Gummy
Sulforaphane is an isothiocyanate formed when glucoraphanin from cruciferous vegetables meets the plant enzyme myrosinase. It is fragile. Gummy manufacturing is not a gentle process, and the two are in tension at several points.
- Heat: Gummy bases are cooked at temperatures that degrade sulforaphane quickly. The manufacturer has to cook the base while protecting the active.
- pH: Sulforaphane degrades faster as pH rises toward neutral and alkaline, so an acidic matrix helps. Pectin bases need a low pH to set, which works with the active, but a gelatin base sets without that acid requirement and can run at a pH where sulforaphane is less stable.
- Water and oxygen: Gummies are wet by design and sit on shelves for months. Sulforaphane degrades with exposure to water and air, so shelf-life stability is a real constraint.
Two Formulation Routes: Precursor or Stabilized Active
Manufacturers take one of two routes. Each carries its own failure mode.
The Precursor Route: Glucoraphanin Plus Myrosinase
This route puts glucoraphanin, the stable precursor, and myrosinase, the enzyme that converts it, into the same gummy. The idea is that the two meet after the consumer chews and swallows, and sulforaphane forms in the body.
The problem is the enzyme. Myrosinase is heat-labile, so the cooking step can destroy it before the gummy reaches a consumer. It is also inactivated by acid, which is one reason little of it survives the stomach; a low-pH gummy base can pose the same problem during storage. If the enzyme is gone, the gummy delivers glucoraphanin only.
Conversion also depends on the body. Without active enzyme, the body falls back on gut bacteria to convert glucoraphanin, and that conversion varies widely from person to person. In a crossover study of glucoraphanin-rich beverages, researchers measured urinary recovery of sulforaphane metabolites at about 5% when the formula lacked active myrosinase and about 70% when the enzyme was included.
The Stabilized Sulforaphane Route
Here the manufacturer starts with sulforaphane already formed and stabilizes it, usually by encapsulation or a proprietary carrier, before it goes into the gummy.
The cost is the first hurdle: these inputs are expensive. The second is that an input described as shelf-stable has not been tested against the heat, moisture, and pH of gummy production. A supplier's stability data rarely covers a gummy matrix.
Engineering the Gummy Matrix Around the Active
Even with the sulforaphane problem solved, the base has to be built to protect it.
Sweetener system: The sweetener choice does more than set the taste. Sugar, syrup, and sugar-free alternatives each change the gummy's water activity, and water activity drives many degradation reactions in the active.
Flavor masking: Sulforaphane and its relatives are pungent and bitter, and masking that in a sweet gummy usually means a flavorist working within tight limits. Too much sweetener or acid added to cover the taste can pull the base out of spec.
Testing: Stability, Dissolution, and Batch Consistency
With an active this sensitive, testing is not a box to check at the end.
- Stability: Real-time and accelerated studies track potency and physical changes across the shelf life, commonly 18 to 24 months for a gummy supplement.
- Dissolution: The test confirms the gummy releases the active in a way the body can absorb. Potency on the label means nothing if the active stays trapped in the matrix.
- Batch consistency: Every lot has to meet the same spec for active content, weight, and texture. Variation between batches is where stability problems surface later.
Label Claims and the Compliance Risk
The engineering problems have a marketing mirror. Sulforaphane is heavily studied for cancer-related endpoints, and the language around it drifts quickly from research to disease claims. A gummy promoted for treating, preventing, or curing cancer or any other condition moves the product into drug territory, and the FDA and FTC enforce against those claims together. The FTC reports it has filed 120 cases challenging supplement health claims over the last decade.
The label itself is the second issue. Many sulforaphane products deliver glucoraphanin rather than sulforaphane, because that is the form that survives manufacturing. If the Supplement Facts panel lists glucoraphanin or broccoli extract, the marketing copy has to describe the product the same way. A brand that sells a glucoraphanin gummy as a sulforaphane gummy has a label accuracy problem on top of the stability problem.
For a contract manufacturer, this means two things. The claims review is part of the job, and the formula and the label have to match. If the route is glucoraphanin plus myrosinase, the panel should say so, and the marketing should stay on structure and function language rather than disease outcomes.
Questions to Ask a Contract Manufacturer
If you are considering a sulforaphane gummy, the manufacturer's answers matter more than the unit price. These questions separate a line that runs hot and wet from one set up for a fragile active.
- How do you protect heat-sensitive ingredients during the cook step?
- Can you share stability data for similar actives in a gummy matrix?
- How do you handle flavor masking without pushing the base out of spec?
- Which tests do you run to confirm release, bioavailability, and batch-to-batch consistency?
Sulforaphane gummies sit at the intersection of chemistry, food science, and supplement compliance. The brands that run the tests and match the formula to the label get a product that holds up, and that is the whole job.